Abstract: An joint treating composition is disclosed that, when administered to mammals in a therapeutically effective amount, can reduce inflammation and even heal injured or diseased skeletal articulations. For example, the joint treating composition is well suited for treating osteoarthritis and other skeletal ailments or injuries. The composition of the present disclosure, for instance, can dramatically decrease various biomarkers related to skeletal health, including reducing tumor necrosis factor serum and protein in the body.

Abstract: A composition containing a plurality of particles containing a core having a lipid matrix including an active ingredient dispersed therein is disclosed. The active ingredient can include a fat-soluble active ingredient. The particles can be contained in a capsule. Also provided are methods for producing a pharmaceutical composition containing a plurality of particles containing a core having a lipid matrix including an active ingredient dispersed therein.

Abstract: The present disclosure is directed to a method for treating a mammal with leaky gut syndrome or having pre-stages of leaky gut syndrome. The method includes administering a composition that includes a native or undenatured type II collagen and/or a probiotic.

Abstract: A composition containing a plurality of particles containing a core having a lipid matrix including an active ingredient dispersed therein is disclosed. The active ingredient can include a fat-soluble active ingredient. The particles can be contained in a capsule. Also provided are methods for producing a pharmaceutical composition containing a plurality of particles containing a core having a lipid matrix including an active ingredient dispersed therein.

Abstract: The present disclosure is directed to a health composition that includes lipid multiparticulates containing one or more probiotics in a lipid matrix formed at least in part from excipients and/or encapsulants having a melting point of less than about 70° C. The one or more probiotics maintain a high level of viability after incorporation into the lipid matrix. In addition, the lipid multiparticulates can maintain the viability and stability if the at least one probiotic in high temperature and high humidity environments.

Abstract: A joint health composition is disclosed that, when administered to mammals in a therapeutically effective amount, can reduce inflammation and joint pain. The joint health composition contains a collagen, and at least one anti-inflammatory adjuvant in the delivery form of lipid multiparticulates. The joint health composition show increased bioavailability and a reduction in inflammation and joint pain in a reduced time period.

Abstract: The present disclosure is directed to a joint-health composition containing one or more anti-inflammatory compounds in a lipid matrix, which improves bioavailability and nutrient availability of the anti-inflammatory compound, as well as allow the release of the anti-inflammatory compound to be controlled over a period of time. The anti-inflammatory compound can include an extract or isolate from a natural source that inhibits one or more of: interleukin-1 expression, interleukin-6 expression, NF-kB expression, cyclooxygenase-2 (COX-2) expression, inducible nitric oxide synthase (iNOS) expression, 5-lipoxygenase biosynthesis, and tumor necrosis factor-? (TNF-?) expression.

Abstract: The present disclosure is directed to an extended release composition containing one or more Boswellia derived compounds in a lipid matrix, which releases the Boswellia derived compound over a period of time. In one embodiment, the composition contains an Boswellic acid compound. In a particular embodiments the Boswellic acid compound is 3-O-acetyl-11-keto-.beta.-boswellic acid (AKBA).

Abstract: A chondroprotective nutraceutical composition and method are disclosed capable of increasing calcium absorption and retention in the skeletal structure of a mammal. The chondroprotective nutraceutical composition contains a collagen. In addition to improving calcium intake, the chondroprotective nutraceutical composition of the present disclosure can also improve various other bone health markers. The composition can be used in the form of a supplement for preventing bone disease and/or treating bone ailments.

Abstract: The present disclosure is directed to method providing effective oral administration of active substance, including pharmaceutical ingredients, nutraceuticals, enzymes or probiotics using a delivery system for optimal bioactivity and absorption of the active substance by the mammal to which the active substance is delivered.

Abstract: The present disclosure is directed to a method for treating an infection in a mammal caused by an infectious agent which binds a receptor of an angiotensin-converting enzyme 2 (ACE-2), leading to its decreased tissue levels. The method includes administering and ACE-2 reducing component to a mammal in a therapeutically effective amount to reduce the amount of the angiotensin-converting enzyme 2 (ACE-2 receptor) in the mammal. Also provided is a method for reducing Furin and TMPRSS2 in an infected mammal or a mammal which may become infected.

Abstract: The present disclosure is directed to a method and composition for improving at least one of joint pain, muscle pain, or fitness in healthy mammals. The method and composition include administering a supplement that includes a type II collagen and a SOD enriched supplement to a healthy mammal that is undergoing or has undergone physical activity or intensive physical activity.

Abstract: The present disclosure is directed to a method of improving at least one of resilience and recovery in healthy mammals undergoing intensive physical activity. The method includes administering a SOD enriched supplement to the healthy mammal during a term of intensive physical activity. The term can be long term or short term, and the mammal can be a healthy trained mammal.

Abstract: A method and composition for increasing muscle protein synthesis in mammals is disclosed. In one embodiment, the mammals are administered a protein building composition comprising at an amino acid derivative including L-carnitine and a nitrogenous organic acid including creatine. In a particular embodiment, the creatine is in an acid resistant capsule delivery form. The ratio of L-carnitine to creatine can be from about 10:1 to about 1:1. The protein building composition can be administered in a monolithic enteric capsule.

Abstract: A method and composition for increasing muscle protein synthesis in mammals is disclosed. In one embodiment, the mammals are administered a protein building composition comprising at an amino acid component including L-carnitine and a nitrogenous organic acid including creatine. In a particular embodiment, the creatine is in a solution with L-carnitine. The ratio of L-carnitine to creatine can be from about 10:1 to about 1:1. The protein building z composition can be administered in a monolithic enteric capsule.

Abstract: A composition containing a plurality of particles containing a core having a lipid matrix including an active ingredient dispersed therein is disclosed. The active ingredient can include a fat-soluble active ingredient. The particles can be contained in a capsule. Also provided are methods for producing a pharmaceutical composition containing a plurality of particles containing a core having a lipid matrix including an active ingredient dispersed therein.